Affiliation: Oregon Health and Science University
- A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinomaC D Blanke
Department of Medicine, Oregon Health and Science Uniiversity, Portland 97201, USA
Ann Oncol 12:1575-80. 2001..A phase II study testing the safety and efficacy of irinotecan (CPT-11). 5-fluorouracil (5-FU), and leucovorin (LCV) was conducted in patients with advanced gastric adenocarcinomas...
- A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancerCharles D Blanke
Oregon Health and Science University Cancer Institute, Portland, OR, USA
Prostaglandins Other Lipid Mediat 75:169-72. 2005..5-FU and leucovorin did not affect COX-2 inhibition by celecoxib. Preliminary data suggest it is safe to combine celecoxib with standard chemotherapeutic agents, in treatment of patients with colorectal cancer...
- State-of-the art therapy for gastrointestinal stromal tumorsCharles D Blanke
Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97201, USA
Cancer Invest 23:274-80. 2005..Questions remain about the optimal dose of imatinib, whether to continue drug in the setting of progressive disease, and how best to prevent or overcome resistance...
- Chemotherapy with cyclooxygenase-2 inhibitors in the treatment of malignant disease: pre-clinical rationale and preliminary results of clinical trialsCharles D Blanke
Oregon Health and Science University, Portland, Oreg, USA
Prog Exp Tumor Res 37:243-60. 2003
- Role of COX-2 inhibitors in cancer therapyCharles Blanke
Oregon Health Science University, 3181 Southwest Sam Jackson Park Rd, Portland, OR 97201, USA
Cancer Invest 22:271-82. 2004
- Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KITCharles D Blanke
Oregon Health and Science University Cancer Center and Portland Veterans Affairs Hospital, Portland, OR, USA
J Clin Oncol 26:620-5. 2008..We conducted a long-term analysis of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status...
- Gastrointestinal stromal tumorsC D Blanke
Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University and Portland Veterans Affairs Medical Center, MC OP28, 3181 S W Sam Jackson Park Road, Portland, OR 97201, USA
Curr Treat Options Oncol 2:485-91. 2001..Its use can serve as a paradigm for designing molecularly targeted therapies for other malignancies...
- Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke
Oregon Health and Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, L 586, Portland, OR 97239, USA
J Clin Oncol 26:626-32. 2008....
- A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancerC D Blanke
Oregon Health and Science University, Portland 97201, USA
Ann Oncol 13:87-91. 2002..This trial was designed to demonstrate the safety and efficacy of TMTX/5-FU/LCV as first-line treatment in ACC...
- Current management of GISTCharles Blanke
Oregon Health and Science University, USA
Clin Adv Hematol Oncol 2:280, 283. 2004
- Celecoxib with chemotherapy in colorectal cancerCharles D Blanke
Oregon Health Sciences University, Portland 97201, USA
Oncology (Williston Park) 16:17-21. 2002..Ongoing clinical trials are currently assessing the potential therapeutic role of COX-2 inhibitors in both prevention and treatment of a diverse range of human cancers...
- Gastrointestinal stromal tumors: imatinib and beyondIan D Schnadig
Oregon Health Sciences University Cancer Institute, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA
Curr Treat Options Oncol 7:427-37. 2006..With the identification of other downstream pathways, several other promising therapies are under current investigation either alone or in combination with imatinib and surgery...
- Gastrointestinal stromal tumors and the evolution of targeted therapyRachel E Sanborn
Oregon Health and Science University Cancer Institute, Portland, Oregon 97239, USA
Clin Adv Hematol Oncol 3:647-57. 2005..Whether this new era of targeted therapy will provide the same advances in more common malignancies will be determined only through the ongoing application and development of clinical trials...
- Current and future management of GISTCharles Blanke
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
Clin Adv Hematol Oncol 4:582-3. 2006
- Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GrMichael C Heinrich
Division of Hematology Oncology, Department of Medicine and Cell and Developmental Biology, Portland Veterans Affairs Medical Center and Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
J Clin Oncol 26:5360-7. 2008..In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing...
- Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignanciesMichael C Heinrich
Department of Medicine, Division of Hematology Oncology, Oregon Health and Science University, USA
J Clin Oncol 20:1692-703. 2002..In this review, we discuss the rationale for and development of KIT tyrosine kinase inhibitors for the treatment of human malignancies...
- Pulmonary and intracerebral plasmacytomas in a patient without multiple myeloma: a case reportBrandon Hayes-Lattin
Division of Hematology and Medical Oncology, Oregon Health and Science University, The OHSU Cancer Institute, Portland, Oregon 97202, USA
Am J Hematol 73:131-4. 2003..Extramedullary plasmacytoma of the lung or brain parenchyma is rare. We report herein a case of extramedullary plasmacytoma involving both the lung and parenchymal brain. We review the literature, comparing and contrasting the current case...
- Molecular correlates of imatinib resistance in gastrointestinal stromal tumorsMichael C Heinrich
Division of Hematology Oncology, Department of Pathology, Oregon Health and Science University Cancer Institute, Oregon Health and Science University, Portland, OR, USA
J Clin Oncol 24:4764-74. 2006..In clinical studies, 75% to 90% of patients with advanced GISTs experience clinical benefit from imatinib. However, imatinib resistance is an increasing clinical problem...
- Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorMichael C Heinrich
R and D 19 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA
J Clin Oncol 21:4342-9. 2003..The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST...
- Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?Rachel Sanborn
Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA
Semin Oncol 32:69-75. 2005....
- Outcome following surgical therapy for gastrointestinal stromal tumorsManeesh Gupta
Department of Surgery, Oregon Health and Science University, Portland, Oregon 97239, USA
J Gastrointest Surg 10:1099-105. 2006..Mitotic index and the presence of metastases remain the primary predictors of postoperative survival. Complete surgical resection, even if multivisceral resection is required, is associated with improved survival...
- Evaluation of the tumor board as a Continuing Medical Education (CME) activity: is it useful?MaryClare Sarff
Division of Surgical, Oregon Health and Science University, Portland
J Cancer Educ 23:51-6. 2008....
- Cancers of the gallbladder and biliary ductsKevin Yee
Department of Medicine, Oregon Health and Science University, Portland 97201, USA
Oncology (Williston Park) 16:939-46, 949; discussion 949-50, 952-3, 956-7. 2002..Of the newer agents, gemcitabine (Gemzar) holds the most promise in the treatment of these difficult malignancies...
- Gefitinib in colorectal cancer: if wishes were horsesCharles D Blanke
J Clin Oncol 23:5446-9. 2005
- The continuum of care: a paradigm for the management of metastatic colorectal cancerRichard M Goldberg
Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Oncologist 12:38-50. 2007....
- Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridizationAbbas Agaimy
Institute of Pathology, Klinikum Nürnberg, 90419 Nurnberg, Germany
Oncol Rep 18:9-15. 2007....
- Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinomaAlan P Venook
Cancer and Leukemia Group B, University of California, San Francisco, CA 94115, USA
Clin Colorectal Cancer 6:536-8. 2007
- NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelinesGeorge D Demetri
J Natl Compr Canc Netw 5:S1-29; quiz S30. 2007....
- Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsGeorge D Demetri
Dana Farber Cancer Institute and Harvard Cancer Center, Boston, MA 02115, USA
N Engl J Med 347:472-80. 2002..Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors...
- Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinibPetri Bono
Department of Oncology, University Central Hospital of Helsinki, Helsinki, Finland
Blood 103:2929-35. 2004..1-259-fold). A high serum SCF/KIT ratio may increase SCF-induced cell signaling with prolonged imatinib treatment, at the time when imatinib treatment is withdrawn, and in patients whose GIST has wild-type receptors...
- Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancerDong W Kim
Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA
Int J Radiat Oncol Biol Phys 67:397-404. 2007..We evaluated paclitaxel-based induction chemoradiotherapy in patients with localized esophageal cancer to determine its feasibility, clinical response, pathologic response, and overall survival...
- Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trialsDaniel J Sargent
North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 23:8664-70. 2005..A shorter-term end point providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice...
- Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinomaAlan P Venook
Cancer and Leukemia Group B, Department of Clinical Medicine, University of California San Francisco, 600 Divisadero Box 1770, San Francisco, CA 94115, USA
Clin Colorectal Cancer 5:292-4. 2005
- Management of gastrointestinal stromal tumors in the imatinib era: selected case studiesRobert S Benjamin
Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
Oncologist 11:9-20. 2006..The management of GIST in these cases required a coordinated, multidisciplinary approach involving medical oncologists, diagnostic radiologists, gastroenterologists, surgeons, and pathologists...
- Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancerKaren L Tedesco
Department of Oncology, Vanderbilt University School of Medicine and Veteran s Affairs Medical Center, Nashville, TN, USA
Int J Radiat Oncol Biol Phys 61:1364-70. 2005..This Phase I study was designed to determine the maximal tolerated dose and dose-limiting toxicity of UFT, leucovorin, and cisplatin when given with radiotherapy in the neoadjuvant treatment of resectable esophageal cancer...
- Targeted therapies in the treatment of colorectal cancer: what managed care needs to knowRowena N Schwartz
University of Pittsburgh School of Pharmacy, 3501 Terrace St, 1104 Salk Hall, Pittsburgh, PA 15261, USA
J Manag Care Pharm 10:S2-13; quiz S14-7. 2004..This review is designed to explore the disease, its current treatment, the expanding field of antiangiogenic treatments, and the implications of these advances for the managed care patient...
- Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trialStephen K Williamson
University of Kansas Medical Center, Kansas City, KS, USA
Am J Clin Oncol 29:116-22. 2006..Based on preclinical data suggesting a dose-dependent synergy between gemcitabine and irinotecan we have conducted a phase II trial in patients with advanced or metastatic esophageal carcinoma...
- Whither irinotecan?Charles D Blanke
J Clin Oncol 23:4811-4. 2005
- Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trialsJoseph M Unger
Southwest Oncology Group Statistical Center, Seattle, WA, USA
J Clin Oncol 24:141-4. 2006..Recognition of this under-representation led to a change in Medicare policy in 2000 to include coverage of routine patient care costs of clinical trials. We conducted an updated analysis of accrual trends...
- Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardiaJ Randolph Hecht
UCLA School of Medicine, Los Angeles, California, USA
Oncology (Williston Park) 17:13-5. 2003..Preliminary data from a phase II trial of this regimen in adenocarcinomas of the gastroesophageal junction show good tolerability and promising activity (response rate of 27%), even in previously treated patients...